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GA 
In this study, we investigated liver injury reports submitted to the FAERS database and 
compared the frequency of reports between drugs that can cause hepatotoxicity via 
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Abstract Drug-induced liver injury (DILI) is a leading reason for preclinical safety attrition and 
post-market drug withdrawals. Drug-induced mitochondrial toxicity has been shown to play an 
essential role in various forms of DILI, especially in idiosyncratic liver injury. This study 
examined liver injury reports submitted to the Food and Drug Administration (FDA) Adverse 
Event Reporting System (FAERS) for drugs associated with hepatotoxicity via mitochondrial 
mechanisms compared with non-mitochondrial mechanisms of toxicity. The frequency of 
hepatotoxicity was determined at a group level and individual drug level. A reporting odds ratio 
(ROR) was calculated as the measure of effect. Between the two DILI groups, reports for DILI 
involving mitochondrial mechanisms of toxicity had a 1.43 (95% CI 1.42–1.45; P < 0.0001) 
times higher odds compared to drugs associated with non-mitochondrial mechanisms of toxicity. 
Antineoplastic, antiviral, analgesic, antibiotic, and antimycobacterial drugs were the top 5 drug 
classes with the highest ROR values. Although the top 20 drugs with the highest ROR values 
included drugs with both mitochondrial and non-mitochondrial injury mechanisms, the top 4 
drugs (ROR values >18: benzbromarone, troglitazone, isoniazid, rifampin) were associated with 
mitochondrial mechanisms of toxicity. The major demographic influence for DILI risk was also 
examined. There was a higher mean patient age among reports for drugs that were associated 
with mitochondrial mechanisms of toxicity [56.1 ± 18.33 (SD)] compared to non-mitochondrial 
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to DILI via mitochondrial mechanisms of toxicity. Univariate logistic regression analysis showed 
that reports of liver injury were 2.2 (odds ratio: 2.2, 95% CI 2.12–2.26) times more likely to be 
associated with older patient age, as compared with reports involving patients less than 65 years 
of age. Compared to males, female patients were 37% less likely (odds ratio: 0.63, 95% CI 0.61–
0.64) to be subjects of liver injury reports for drugs associated with mitochondrial toxicity 
mechanisms. Given the higher proportion of severe liver injury reports among drugs associated 
with mitochondrial mechanisms of toxicity, it is essential to understand if a drug causes 
mitochondrial toxicity during preclinical drug development when drug design alternatives, more 
clinically relevant animal models, and better clinical biomarkers may provide a better translation 
of drug-induced mitochondrial toxicity risk assessment from animals to humans. Our findings 
from this study align with mitochondrial mechanisms of toxicity being an important cause of 
DILI, and this should be further investigated in real-world studies with robust designs. 
KEY WORDS Mitochondrial toxicity; FAERS database; Adverse event reporting; Drug-
induced liver injury; Hepatotoxicity 
Abbreviations: AE, adverse event; CI, confidence interval; CNS, center nervous system; DILI, 
drug-induced liver injury; DNA, deoxyribonucleic acid; FAERS, FDA’s Adverse Event 
Reporting System; FDA, US Food and Drug Administration; MedDRA, Medical Dictionary for 
Regulatory Activities; NCTR-LTKB, National Center for Toxicological Research-Liver Toxicity 
Knowledge Base; NSAID, nonsteroidal anti-inflammatory drugs; ROR, Reporting Odds Ratio 
 
1. Introduction  
Severe drug-induced liver injury (DILI) is a rare, potentially life-threatening adverse event with 
an incidence of 10–15 cases per 10,000 to 100,000 patients per year
1-4
. The clinical profile of 
DILI is challenging to diagnose as it can mimic almost any type of liver disease
5,6
 and mild, 
asymptomatic transaminase elevations may mimic those caused by diet
7
. Prediction of liver 
injury remains a challenge for the pharmaceutical industry, regulators, and clinicians
5
. DILI 
symptoms range from non-specific mild elevations in liver enzymes (aminotransferases) to 
severe liver illnesses such as cirrhosis or acute hepatitis
5,6
 and there is no specific biomarker that 











2 | P a g e  
 
There are two types of DILI: intrinsic (i.e., dose-dependent) and idiosyncratic (i.e., dose-
independent)
6
. A well-known example of intrinsic DILI is acetaminophen-induced liver injury, 
as it is dose-dependent, the onset is hours to days, and predictable
9
. On the other hand, 
idiosyncratic DILI is not dose-dependent, occurs in a small portion of drug-exposed individuals, 
its onset is days to weeks, and unpredictable
9
. Idiosyncratic DILI is highly dependent on 
environmental and host factors that alter the susceptibility of individual patient responses to the 
drug. Hamilton et al.
10
 suggested that DILI is the convergence of three influencing risk factors: 
host factors, environmental factors, and drug-specific factors. Host-related risk factors include 
genetics, ethnicity, gender, comorbidities, alterations in drug transport, drug clearance 
capabilities, age, and mitochondrial function variability
10
. Environmental risk factors include 
lifestyle, viral co-infection, co-prescriptions, diet, and alcohol consumption
10
. Finally, drug-
specific risk factors include the relationship of applied dose (exposure) and chemical structure 
with reactive metabolite formation, mitochondrial dysfunction, and lipophilicity
10-12
. Therefore, 
mechanisms of DILI, whether intrinsic or idiosyncratic, are a multivariable, highly complex 
process that varies from patient to patient and is influenced by host, environmental, and drug-




In recent years, drug-induced mitochondrial toxicity has been shown to play an essential role 
in intrinsic and idiosyncratic DILI. Many medications from different drug classes, such as 
antidiabetic, antilipidemic, antiviral, antibiotic, anti-inflammatory, and antipsychotic agents have 
toxicities mediated by mitochondrial mechanisms, which may contribute to DILI
13
. 
Mitochondrial toxicants affect mitochondrial homeostasis by numerous mechanisms such as 
oxidative stress, inhibition or uncoupling of respiratory complexes of electron transport chain, 
impairment of mitochondrial replication or promoting mitochondrial DNA damage
14
. Drug-
induced mitochondrial toxicity is difficult to be detected in standard preclinical animal testing 
models and requires specific studies to examine disruptions in liver energy status
15
. Only 





 beyond changes in blood lactate. With these inadequacies, a 
drug candidate can enter human clinical trials only to fail for evidence of mitochondrial 
toxicity
18,19
. Examples of non-mitochondrial toxicity mechanisms that drive DILI are generation 
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immune response pathways, or disruption of cellular homeostasis
20
. This study evaluates the 
frequency of reports of hepatotoxicity injury in drugs that cause DILI with mitochondrial and 
non-mitochondrial mechanisms.   
Patient demographics influence risk or susceptibility for DILI. Boelsterli and Lim
21
 
indicated that older age and female gender were important susceptibility factors for DILI; 
however, the reasons were still unknown. There are no clinical studies that link the sensitivity of 
the female gender to DILI caused by mitochondrial dysfunction. Amacher et al.
22
 indicated that 
women are more susceptible to DILI than men. Several hypotheses were proposed to explain 
gender differences in susceptibility, including pharmacokinetic or pharmacodynamic differences, 
interactions of sex hormones with signaling molecules, and a difference in immune system 
responses
22
. Similarly, it is believed that older adults are more susceptible to DILI caused by 
mitochondrial dysfunction. The review published by Will et al.
13
 indicated that the most 
commonly used prescription and over-the-counter medications for geriatric patients, such as 
antilipidemic, pain, and heartburn medications, had published reports of toxicities linked to 
mitochondrial dysfunction
13
. As the United States’ elderly population is growing rapidly, 
identifying and addressing risk factors of DILI, where mitochondrial dysfunction may play a 
substantial role in adverse events, will be beneficial to this vulnerable patient population. 
Therefore, in this study, we evaluated the patient age and gender associated with DILI reports 
(measured by reporting odds ratio) for hepatotoxicants with mitochondrial and non-
mitochondrial injury mechanisms.   
Given that mitochondrial dysfunction is a common characteristic of drugs that cause liver 
injury, a better understanding of the association between the probability of liver injury induced 
by drugs that are mitochondrial toxicants and the influence of patient’s age and gender would be 
beneficial for clinicians and drug developers. If a drug is associated with mitochondrial 
mechanisms of liver injury, clinicians could incorporate mitochondrial injury-specific 
biomarkers into clinical trials
23-25
. Additionally, the development of clinically relevant animal 




This study investigated liver injury reports submitted to the US Food and Drug 
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of reports between drugs that can cause hepatotoxicity via mitochondrial mechanisms and those 
without mitochondrial mechanisms of toxicity. Additionally, we determined if there were age 
and gender differences associated with DILI reports involving drugs with or without 
mitochondrial toxicities.  
2. Methods 
2.1. Study design 
2.1.1. Data source 
FAERS database is the largest national repository of spontaneous drug event reports, having 
accumulated over 28 million adverse events reports. Healthcare professionals, patients, 
manufacturers, and lawyers can submit potential drug-induced adverse events of small and large 
therapeutic (biologics) classes and medical devices to the FAERS database. The FAERS 
database has a vital role in post-market drug surveillance in terms of detection and 
characterization of drug and device-related adverse events.   
We extracted adverse event reports from the FAERS database for the timeframe from 
January 1998 to May 2019. In this study, the reports included severe adverse events, such as 
hospitalization, disability, or death. The types of reports were classified by FAERS as direct, 
expedited, or periodic. Direct reports were submitted to FDA from consumer or health care 
professionals; whereas, expedited reports were sent from the manufacturer within 15 days of 
severe adverse events occurrence not included in the product label
26
. Adverse drug event reports 
considered periodic were submitted from manufacturers, included in the label, and sent to the 
FDA quarterly or annually
26
. The main selection criterion was “primary suspect” drugs. 
“secondary suspect” drugs were excluded because of the greater uncertainty of the association 
between the drug and the reported adverse events. FAERS reports were coded using the 
MedDRA (Medical Dictionary for Regulatory Activities) terms for DILI
27
. Although DILI has 
complex clinical symptoms, there has been documentation for the utilization of the FAERS 
database to investigate emerging DILI adverse events for newly marketed drugs
8
.  
2.1.2. Inclusion/exclusion criteria 
Drugs that cause liver injury have been annotated using the United States National Center for 
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hepatotoxic descriptions from the FDA-approved drug labeling regulatory documents as well as 
evaluating causality evidence in the literature
28
. This database was created by the FDA to help 
clinicians, toxicologists, and researchers access information on DILI annotation of various 
drugs
28,29
. NCTR-LTKB serves as a centralized source to study the mechanism of DILI and the 
development or validation of emerging biomarkers and predictive models
29
. This is the largest 
publicly available annotated DILI dataset containing three groups based on their potential to 
cause liver toxicity [Most DILI concern-(192 drugs), Lesser DILI concern-(278 drugs), and No-
DILI concern (312 drugs)] with confirmed causal evidence connecting a drug to liver injury
28
. 
The FAERS database uses FDA drug labeling information for the classification of drugs 
according to their potential to cause DILI. This study utilized drugs with “most-DILI concern”, 
which were defined based on hepatotoxicity resulting in market withdrawal (in US and ex-US), 
black box warning, or high severity of liver injury noted as part of the warning and precautions 
label
28-30
.  Therefore, both mitochondrial and non-mitochondrial mechanisms of toxicity groups 
are associated with severe hepatic injury. 
The study drugs represented various drug classes such as analgesic, anti-inflammatory, 
antidepressant, antibiotic, antidiabetic, and antineoplastic agents. Most of these drugs had been 
withdrawn, have boxed warnings, or have warnings and precautions for liver injury in their 
prescribing labels. The details of DILI severity categories based on the DILI description are 
included in the drug labeling: severity level 1; steatosis, level 2; cholestasis and steatohepatitis, 
level 3; liver aminotransferases increase, level 4; hyperbilirubinemia, level 5; jaundice, level 6; 
liver necrosis, level 7; acute liver failure, and level 8; hepatotoxicity
28
. Examples of withdrawn 
drugs include bromfenac, chlorzoxazone, troglitazone, and trovafloxacin, which have been 
assigned a severity level of 8, suggesting evidence of fatal hepatotoxicity. Drugs such as 
bosentan, danazol, ketoconazole, nefazodone, tolcapone, and valproic acid have box warning in 
their product labeling and have severity categories ranging from 3 to 8.   
2.1.3. Classification of drugs as mitochondrial toxicants 
Drugs with mitochondrial mechanisms of toxicity were defined by literature evidence of 
mitochondrial injury mechanisms (yes or no) of in vitro (e.g., cellular production of reactive 
oxygen species via oxidative stress, inhibition or uncoupling of respiratory complexes of 
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inhibition of mitochondrial fatty acid oxidation or mitochondrial DNA damage, etc.)
31-42
 or in 
vivo mitochondrial toxicity from animal studies (evidence of impairment of oxidative 
phosphorylation complexes or histopathological alterations of mitochondria in in vivo animal 
models, etc.)
43,44
. Our classification was based on the parent drug-induced toxicity (direct impact 
on mitochondria) and not the metabolite. Possible drug effects on mitochondrial biogenesis or 
respiratory capacity were not considered. Drugs with the non-mitochondrial mechanisms of 
toxicity were defined by literature evidence of the alternative mechanisms of injury or lack of 
evidence. It is important to note that 8.2% of drugs had no literature evidence of the type of 
toxicity mechanism, meaning it could be a mitochondrial or non-mitochondrial mechanism. 
Furthermore, the non-mitochondrial mechanisms of toxicity drugs are not proven to have non-
mitochondrial mechanisms. For these drugs, there is simply no evidence of mitochondrial 
mechanisms of toxicity information that is publicly available yet.   
2.2. Outcome 
We determined the number of reports for hepatotoxicity at a group level and an individual drug 
level using the Reporting Odds Ratio (ROR). As shown in Table 1, we calculated total 
hepatotoxicity and all other adverse events for both the DILI groups. For ROR calculations, 
numerators are derived by multiplying the hepatotoxicity reports for mitochondrial mechanisms 
of toxicity drug group with all other adverse event reports of non-mitochondrial mechanisms of 
toxicity per drug group. The denominator is calculated by multiplying hepatotoxicity adverse 
event reports of non-mitochondrial mechanisms of toxicity with all the adverse events reported 
for mitochondrial mechanisms of toxicity per drug group
45
. Therefore, the ROR for drugs 
associated with mitochondrial mechanism of toxicity was 1.43 
[ROR=(40,343×1,342,486)/(586,989×64,358)=1.43].   
Insert Table 1 
We also examined the RORs at the individual drug level, as shown in Table 2. A case 
(hepatotoxicity reports) or non-case (all other adverse event reports) disproportionality approach 
was utilized by creating a two-by-two contingency table, as demonstrated below using 
acetaminophen as an example
45
. During this timeframe, a total of 383,540 hepatotoxicity reports 
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calculations, numerators are derived by multiplying the hepatotoxicity reports for a drug of 
interest with all other adverse events reports. The denominator is calculated by multiplying 
hepatotoxicity adverse event reports of all other drugs (excluding acetaminophen) with all the 
adverse events reported with a drug of interest
45
 (ROR for 
acetaminophen=[8,509×27,852,908)/(51,732×383,540)=11.94]. Within the timeframe, a ROR 
higher than 1 for a drug indicates a higher proportion of severe liver injury reports for a drug of 
interest than all the other drug reports in the database. In this case, acetaminophen was 
associated with proportionally more reports for serious liver adverse events than other drugs in 
the database.  
Insert Table 2 
2.3. Association of age, gender, and other factors in two groups of DILI (mitochondrial and non-
mitochondrial mechanisms of toxicity) 
Mitochondrial function declines with aging
13
; therefore, we evaluated if reports of severe DILI 
were disproportionately associated with older patient age, indicating potential susceptibility to 
DILI from mitochondrial mechanisms of toxicity. Furthermore, since gender may play an 
important role in the sensitivity of DILI, we also evaluated the frequency of reports according to 
patient gender. The mean and standard deviation (SD) of patient age were calculated and 
compared between DILI reports caused by drugs associated with mitochondrial mechanisms of 
toxicity and DILI reports associated with non-mitochondrial mechanisms. Patient age was 
dichotomized into ≤65 years or >65 years for comparison. Other factors, including drug severity 
class, patient weight, report type, and label section, were examined in a descriptive analysis.  
2.4. Statistical analysis 
Descriptive statistics were used to compare the gender and age of reports for the DILI drug 
groups associated with mitochondrial mechanisms of toxicity and associated with non-
mitochondrial mechanisms. The statistical significance of differences in categorical variables 
such as age group, DILI severity, drug label, and report type between two categories of DILI 
drugs was examined using the chi-square test. Whereas, differences in continuous variables such 
as mean patient age between the two categories of hepatotoxic drugs were compared with the 
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gender with mitochondrial mechanisms of toxicity DILI group (against non-mitochondrial 
mechanisms of toxicity DILI group) was determined using univariate logistic regression 
analysis. ROR calculations were carried out using a two-by-two contingency table using 
OpenEpi (version 3.01; Centers for Disease Control and Prevention), which calculates 95% CI 
and P-values via Taylor series
46
. Chi-square tests were performed with SAS version 9.4 (SAS 
Institute, Cary, NC, USA), and two-sided t-tests were performed at the 0.05 significance level 
via GraphPad Prism version 8 (La Jolla, CA, USA). All statistical tests were two-sided with a 
significance level at 0.05. 
3. Results 
We included 192 drugs classified as having the highest DILI risk (“Most-DILI concern”) via the 
NCTR-LTKB database. Out of these 192 drugs, 134 drugs had searchable FAERS reports, while 
the remaining 58 drugs were either withdrawn before our study period or were withdrawn from 
the European market before US approval. Therefore, the final data set contained 134 drugs, 
which were categorized as 56 drugs causing hepatotoxicity via mitochondrial mechanisms, and 
78 drugs were classified as causing hepatotoxicity via non-mitochondrial mechanisms.   
Table 3 indicates the characteristics of the event reports included in the study. A total of 
104,701 adverse event reports were extracted from FAERS for the period spanning January 
1998 to May 2019. Of these, 40,343 (38.5%) reports of hepatotoxicity were for drugs that were 
associated with mitochondrial mechanisms of toxicity, whereas 64,358 (61.5%) reports of 
hepatotoxicity were for drugs associated with non-mitochondrial mechanisms of toxicity. 
Furthermore, drugs were categorized based on the NCTR-LTKB severity classification. There 
was a statistically significant difference in DILI severity (P < 0.0001) between the two groups of 
DILI drugs (mitochondrial mechanisms compared to non-mitochondrial mechanisms). There 
was a 5.5 percentage point difference in reports for more severe DILI (liver 
failure/hepatotoxicity) for drugs associated with mitochondrial mechanisms of toxicity 
compared to non-mitochondrial mechanisms (76.3% compared to 70.8%, respectively, P < 
0.0001). As shown in Table 3, the FAERS reports were classified based on the drug label 
section for liver injury; there was a statistically significant difference in drug labels (P < 0.0001) 
between the two groups of DILI drugs (mitochondrial mechanisms compared to non-
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drugs had a box warning label as compared to 19.8% of non-mitochondrial mechanisms of 
toxicity drugs, and 64.9% of mitochondrial mechanisms of toxicity drugs had warning and 
precautions label as compared to 79.1% of non-mitochondrial mechanisms of toxicity drugs. For 
drugs withdrawn due to hepatotoxicity, there were high numbers of reports (n = 4227, 10.5%) 
for drugs that are associated with mitochondrial toxicity mechanisms, compared to a lower 
number of reports (n = 747, 1.2%) for drugs with non-mitochondrial mechanisms of toxicity (P 
< 0.0001). Over 88% of reports were expedited, while the rest of the reports were either direct or 
periodic. In summary, there was a statistically significant difference between drug severity 
classification, label, and liver injury severity according to the drug’s ability to cause toxicity 
through mitochondrial mechanisms.  
We also examined patient bodyweight, but 79%–81% of the reports did not have this 
information documented. Among the 19%–21% of reports where the bodyweight data was 
present, the average difference between the two groups of DILI drugs (mitochondrial compared 
to non-mitochondrial mechanisms) was only 1.6 kg (68.6 ± 20.8 compared to 70.2 ± 23.4; P < 
0.0001). In this case, the small P-value may be because the large sample size overpowered the 
comparison. As large numbers of the reports were missing bodyweight, further analysis was not 
performed.  As shown in Table 3, a higher percentage of males were the subjects of 
hepatotoxicity reports via mitochondrial mechanisms compared to the subjects of reports 
involving hepatotoxicity via the non-mitochondrial mechanisms (49.1% compared to 37.8%, P 
< 0.0001). About 7% to 8.3% of reports were missing information about the patient’s gender.   
Insert Table 3 
Table 3 presents the difference in the mean and distribution of age among the two groups. 
The patient’s age was recorded in more than 71% of the reports from both the groups. As shown 
in Table 3, there was a statistically significant difference (P < 0.0001) between the mean age of 
patients with hepatotoxicity in drugs that are associated with mitochondrial mechanisms [56.1 ± 
18.33 (SD)] compared to non-mitochondrial mechanisms of toxicity [48 ± 19.53 (SD)]. In other 
words, reports involving drugs associated with mitochondrial mechanisms of hepatic toxicity 
displayed a higher mean age than reports for drugs associated with non-mitochondrial 
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Fig. 1 indicates the ROR values of drugs associated with mitochondrial mechanisms of 
toxicity; benzbromarone, troglitazone, isoniazid, rifampin, and nimesulide had the highest ROR 
values in the group. Fig. 2 indicates the ROR values of drugs associated with non-mitochondrial 
mechanisms of toxicity; telithromycin, gemtuzumab ozogamicin, mexiletine, dactomycin, and 
disulfiram had the highest ROR values in the group. Table 4 indicates the top 20 drugs with the 
highest ROR values in both groups of hepatotoxicants. The top 20 drugs with the highest ROR 
values included drugs with either mitochondrial or non-mitochondrial injury mechanisms. The 
top 4 drugs, which had ROR values higher than 18 (benzbromarone, troglitazone, isoniazid, 
rifampin), were associated with mitochondrial mechanisms of toxicity. Furthermore, the top two 
drugs, benzbromarone, and troglitazone were withdrawn from the market.   
Insert Table 4 
Insert Figs. 1 and 2 
Table 5 indicates the RORs between the two groups of drugs that caused liver injury via 
mitochondrial compared to non-mitochondrial mechanisms. Between the two DILI groups, 
reports for DILI involving mitochondrial mechanisms of toxicity had a 1.43 (95% CI 1.42–1.45; 
P < 0.0001) times higher odds compared to drugs associated with non-mitochondrial 
mechanisms of toxicity. The univariate logistic regression model was used after dichotomizing 
age and gender. Table 6 indicates a statistically significant risk association of age or gender with 
hepatotoxic drugs with mitochondrial toxicity mechanisms. Reports of liver injury were 2.2 
(odds ratio: 2.2, 95% CI 2.12–2.26) times more likely to be associated with older patient age, as 
compared with reports involving patients under 65 years of age. On the other hand, female 
patients were 37% less likely to be subjects of liver injury reports for drugs associated with 
mitochondrial mechanisms of toxicity compared to males (Odds Ratio 0.63, 95% CI 0.61–0.64). 
Supporting Information Tables S1 to S7 contain DILI reports, all adverse event reports, ROR, 
and 95% Confidence Interval (CI) for all the drugs evaluated in the study.  
Insert Tables 5 and 6 
Fig. 3 indicates the totality of all ROR scores of DILI drugs with mitochondrial or non-
mitochondrial mechanisms of toxicity. Drugs from the antineoplastic, antiviral, analgesic, 
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ROR scores. Drugs from the antidiabetic, antiretroviral, anti-inflammatory, anti-Parkinson, 
vasoactive, neuroprotective, and antihyperlipidemic drug classes were primarily associated with 
mitochondrial mechanisms. Alternatively, leukotriene pathway modulators, alcohol antagonists, 
CNS stimulants, and platelet inhibitor drug classes were the drugs with non-mitochondrial 
mechanisms having higher RORs. Figs. 4 and 5 categorize these two groups of drugs based on 
the drug label section and severity class. We did not observe any notable trend between 
mitochondrial and non-mitochondrial mechanisms and drug label section, or severity class. 
Insert Fig. 3–5 
4. Discussion 
Prediction and characterization for DILI during preclinical drug development and post-approval 
remains a challenge for the pharmaceutical industry, toxicologists, clinicians, physicians, health 
authorities, and regulators
5
. Characterizing DILI has been a challenge due to its unpredictability, 
lack of accurate biomarkers, poorly defined pathogenesis, and its potential to cause fatal liver 
failure
5
. In the past two decades, drug-induced mitochondrial dysfunction has been established as 
an important contributing mechanism associated with liver, muscle, heart, kidney, and central 
nervous system toxicity
13
. Mitochondrial dysfunction is one of the reasons known to cause 
muscle toxicity by HMG-CoA (3-hydroxy-3-methylglutaryl coenzyme A) reductase inhibitor 
(cerivastatin), cardiovascular toxicity by anthracyclines (daunorubicin, doxorubicin, idarubicin), 




We calculated the ROR for reports of severe hepatotoxicity adverse events among drugs 
with the highest risk for DILI, for drugs having mitochondrial or non-mitochondrial mechanisms 
of toxicity. Brinker et al.
8
 indicated that various measures of disproportionate reporting of 
adverse events such as Proportional Reporting Ratio, Multi-item Gamma Poisson Shrinker, and 
the Bayesian Confidence Propagation Neutral Network had been used in analyses of surveillance 
databases. Each of these methods may have different strengths and limitations and may lead to 
different sensitivity and specificity for a drug's risk reporting
8
. Various health regulatory 
authorities use different statistical measures for reporting. For example, the European Medicines 
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Regulatory Agency uses Multi-item Gamma Poisson Shrinker. Whereas, the World Health 
Organization has utilized the Bayesian Confidence Propagation Neutral Network method for 
reporting
8
. These reporting measures have been used to generate hypotheses and do not infer 
adverse event-causal associations. It has been suggested that there is not one single measure of 
effect that is superior to the others
8,51,52
. Our study utilized reporting odds ratios to characterize 
the frequency of liver injury reports as it is a straightforward and frequently used measure for the 
analysis of FAERS data
45,53-57
.  
The review published by Will et al.
13
 indicated that the most commonly used 
prescriptions and over the counter medications for geriatric patients had published reports of 
various toxicities linked to mitochondrial dysfunction. Our study reported that reports for DILI 
involving mitochondrial mechanisms of toxicity had a 1.43 (95% CI 1.42–1.45; P < 0.0001) 
times higher odds compared to drugs associated with non-mitochondrial mechanisms of toxicity. 
The ROR scores with the highest risk of liver injury based on mitochondrial or non-
mitochondrial mechanisms were highest for drugs from the antineoplastic, antiviral, analgesics, 
antibiotics, and antimycobacterial classes. This finding agreed with the published literature. 
Sonawane et al.
26
 indicated that antineoplastic, analgesics, and antibiotics were among the top 10 
drugs that reported severe adverse events in the FAERS database from 2006 to 2014. 
Additionally, our study observed that over 88% of adverse reports were expedited, while the rest 
of the reports were either direct or periodic in both drug categories. This observation also agreed 
with the published literature. Sonawane et al.
26
 also reported that expedited reports were the most 
common and over 72% of all serious adverse events with available data on the report type.  
Antidiabetic, antiretroviral, anti-inflammatory, anti-Parkinson, vasoactive, 
neuroprotective, antihyperlipidemic drug classes were primarily associated with mitochondrial 
toxicity mechanisms. In recent years, an impaired mitochondrial function has been documented 
as one of the critical factors in inflammation, sarcopenia, metabolic (obesity, type 2 diabetes, 
non-alcoholic fatty liver disease), and neurodegenerative diseases (Parkinson’s, Alzheimer’s, 
Huntington’s diseases)
13,58-60
. Patients with reduced mitochondrial function occurring as a 
manifestation of their underlying disease state may be more vulnerable to drugs that cause 
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modulators, alcohol antagonist, CNS stimulants, and platelet inhibitors were drug classes that 
were primarily associated with non-mitochondrial toxicity mechanisms.   
We identified statistically significant differences (P < 0.0001) in drug severity 
classification, label section for liver injury, and report type between these two mechanisms for 
DILI.  For drugs withdrawn for liver injury, there were a higher number of hepatotoxicity reports 
(10.5%) associated with mitochondrial than non-mitochondrial mechanisms (1.2%). Dykens and 
Will (2007) noted that 38 marketed drugs withdrew from the market between 1994 and 2006.  
Among these, for cerivastatin, nefazodone, troglitazone, and tolcapone, there was substantial 
evidence of mitochondrial-induced organ toxicity
48
. Therefore, our observations agreed with 
reports in the medical literature of drug-induced mitochondrial dysfunction playing an important 
role in drug withdrawal. Furthermore, Boelsterli and Lim
21
, in 2007, suggested that several 
drugs, such as amiodarone, dantrolene, diclofenac, isoniazid, lamivudine, leflunomide, 
mefenamic acid, nimesulide, perhexiline, simvastatin, stavudine, sulindac, tolcapone, 
troglitazone, trovafloxacin, and valproic acid, are associated with idiosyncratic DILI with a clear 
link to mitochondrial toxicity. Many of these drugs reported a relatively higher ROR in our 
study. 
Our study reported an older mean patient age [56.1 ± 18.33 (SD)] associated with reports 
for drugs that cause DILI via mitochondrial mechanisms compared to mean age [48 ± 19.53 
(SD)] associated with reports for drugs that cause injury via non-mitochondrial mechanisms (P 
< 0.0001). This was further substantiated in a univariate logistic regression analysis where 
reports of liver injury were 2.2 (odds ratio: 2.2, 95% CI 2.12–2.26) times more likely to be 
associated with older patient age, as compared with reports involving patient ages under 65 
years. This finding is consistent with physiological information indicating age as a risk factor for 
both mitochondrial DNA abnormality and increased oxidative stress-related injury
59
. There is 
evidence that mitochondrial function declines with age, including the role of mitochondrial 
DNA mutation, increased production of reactive oxygen species, and the dysfunction in 
oxidative phosphorylation pathways
58
. The hallmark of mitochondrial aging includes a 
decreased mitochondrial number, reduced mitochondrial function, and individual electron 
transport chain activities
13
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Therefore, older age populations may be more vulnerable to hepatotoxic drugs associated with 
mitochondrial mechanisms of toxicity.   
Our study indicated that female patients were 37% less likely to report liver injury 
adverse events for drugs associated with mitochondrial mechanisms of toxicity compared to 
males. There are conflicting reports associating male gender as a susceptibility factor for DILI, 
and a clear link for this association is absent in the literature
21,61
. Several articles allude to the 
potential involvement of a reactive metabolite, and differences in pharmacokinetics, 





Mitochondria play an important part in DILI, including idiosyncratic liver injury. There have 
been various proposed mechanisms for mitochondrial involvement in DILI
59
. There is a gap in 
the literature describing the differences in clinical outcomes for patients who experienced DILI 
from mitochondrial mechanisms of toxicity as compared with non-mitochondrial mechanisms of 
toxicity drugs. There are limitations in detecting drugs that have mitochondrial liability in the 
drug development phase of the discovery. For the most part, drug-induced mitochondrial 
toxicity does not reveal itself in animal models due to the young age, lack of genetic divergence, 
health status, and lack of concomitant drug exposure
13
. Therefore, drug-induced mitochondrial 
toxicity is often idiosyncratic, meaning it is not predictable until a large population is 
exposed
21,60
. Based on this study, we provide evidence of a higher proportion of reports of 
severe liver injury adverse events among drugs associated with mitochondrial mechanisms of 
toxicity as compared with non-mitochondrial mechanisms of toxicity. Furthermore, we found 
that reports of liver injury were 2.2 (odds ratio: 2.2, 95% CI 2.12–2.26) times more likely to be 
associated with older patient age, as compared with reports involving patients ages under 65 
years. This finding aligns with the theory that age is a susceptibility factor in liver injury via the 
mitochondrial mechanisms of toxicity. 
6. Limitation 
The FAERS database describes adverse event reports but does not include information about the 
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relationships between drugs and safety adverse events cannot be determined for drugs according 
to mitochondrial or non-mitochondrial mechanisms of toxicity. For example, the population 
incidence of DILI may be higher for drugs associated with non-mitochondrial mechanisms than 
mitochondrial mechanisms of toxicity. Nevertheless, researchers and health authorities have 
used the FAERS database for adverse event signal identification, developing ideas, and 
hypothesis generation despite this limitation. The hypothesis and ideas generated using this 
database could serve as a foundation for more robust study designs, and for in vitro or in vivo 
studies investigating the causal relationship of a drug with liver injury. The FAERS database 
provides a suitable source to evaluate the volume and characteristics of adverse event reports for 
marketed medications. Furthermore, factors such as age, gender, weight, drug severity class, and 
label section of FAERS reports can provide valuable insights to health authorities during the 
post-market surveillance of marketed medications.   
The FAERS database is a spontaneous reporting system with limitations when used for 
drug safety research, including the potential for under or over-reporting events, duplicate reports, 
influence of media, and uncertainty of reported events
8,62
. For example, troglitazone received 
significant media attention due to a class-action lawsuit which called attention to its DILI risk. 
Therefore, troglitazone may have a higher number of hepatotoxicity reports than some drugs that 
did not receive media attention. Moreover, the FAERS database could be associated with the 




Mitochondria have a diverse role in the pathophysiology of DILI. In current literature, 
most of the mitochondrial-induced toxicity is derived from in vitro studies. In vitro assays using 
immortalized cell lines or primary human hepatocytes have their limitations as they generally 
lack competent metabolic function, xenobiotic biotransformation capacity, appropriate drug 
receptors and transporters, and cellular architecture. Therefore, it is unclear how mitochondrial in 
vitro mechanisms truly translate to liver injury outcomes in humans; there appear to be strong 
associations as outlined here. 
Characterizing DILI drugs based on mitochondrial dysfunction versus other mechanisms 
may have limitations. For acetaminophen, mitochondrial dysfunction plays an essential role in 
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Mechanistically, acetaminophen produces a reactive metabolite leading to disruption of cellular 
homeostasis. However, acetaminophen as a parent drug does not directly affect the mitochondrial 
respiratory chain or cause direct toxicity to mitochondria. Therefore, we included acetaminophen 
in non-mitochondrial DILI drugs while considering that mitochondrial dysfunction plays an 
important role in acetaminophen-induced liver injury. Moreover, given the limitations of the data 
source we were unable to discern intrinsic from idiosyncratic DILI. 
Patients with an underlying condition such as obesity may be more vulnerable to drugs 
that cause toxicity via mitochondrial mechanisms; thus, we attempted to include patient weight 
in our study.  However, about 79%–81% of the reports missed the bodyweight information; 
therefore, the effect of patient weight was not examined. The study may also have several 
unmeasured confounding factors as patient comorbidities, pre-existing liver disease, and 
concomitant drug use is not captured in FAERS reports. Additionally, the findings regarding age 
and gender are unadjusted; therefore, it should be used merely for hypothesis generation. 
Moreover, gender bias may be due to disease demographics. Some of the DILI drugs with 
mitochondrial toxicity mechanisms are prescribed for diseases with a higher male predisposition. 
For example, benzbromarone is prescribed for gout, which has six times higher occurrence in 
males
63
. Similarly, isoniazid and rifampin are prescribed for the treatment of tuberculosis, which 
has two times higher occurrence in males
64
.  
ROR depends on the reporting rates of liver injury adverse events and all other adverse 
events reports in compared drug classes. DILI drugs associated with non-mitochondrial 
mechanisms of toxicity have a significantly higher number of non-hepatic adverse events 
reports. Therefore, we are not sure if larger ROR values are due to the higher reporting of 
hepatotoxicity in the drugs with mitochondrial mechanisms of toxicity, or higher reporting of 
non-hepatic adverse events reported for the drugs with non-mitochondrial mechanisms of 
toxicity.   
For this analysis, we utilized ROR, which is a disproportionality measurement of 
spontaneous reports and not a method to measure drug-related risks quantitatively. Regulatory 
actions in response to safety concerns related to age and gender using the FAERS database must 
be determined via individual cases to determine causality. Despite these database limitations, we 
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associated with a higher proportion of adverse event reports than drugs having non-
mitochondrial mechanisms of toxicity. Additionally, age may play a role in susceptibility to 
DILI via mitochondrial mechanisms of toxicity. Our findings from this study align with 
mitochondrial mechanisms of toxicity being an important cause of DILI, and this should be 
further investigated in real-world studies with robust designs. 
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Table 1 Reporting odds ratio estimates for DILI drug groups (FAERS reports). 
DILI groups Hepatotoxicity All other adverse events Total 
Drugs associated with mitochondrial 
mechanisms of toxicity 
40,343 586,989 627,332 
Drugs associated with non-mitochondrial 
mechanisms of toxicity 
64,358 1,342,486 1,406,844 
Total 104,701 1,929,475 2,034,176 
 
Table 2 Example reporting odds ratio estimate for an individual drug: acetaminophen (FAERS 
Reports). 
Drug Hepatotoxicity All other adverse events Total 
Acetaminophen 8,509 51,732 60,241 
All other drugs of any type 383,540 27,852,908 28,236,448 
Total 392,049 27,904,640 28,296,689 
 
Table 3 Characteristics of patients and hepatotoxic drugs associated with mitochondrial 
mechanisms of toxicity compared to non-mitochondrial mechanisms.  





mechanism (78 drugs) 
FAERS report counts (n) 40,343 (38.5%) 64,358 (61.5%) 
Reports based on NKTR drug severity classification  
3 - Liver aminotransferases 
increase 
0 (0%) 3,048 (4.7%) 
4 - Hyperbilirubinemia 1,958 (4.9%) 2,292 (3.6%) 
5 - Jaundice 7,526 (18.7%) 13,392 (20.8) 
6 - Liver necrosis 0 (0%) 35 (0.05%) 
7 -Acute liver failure 4,581 (11.3%) 17,207 (26.7%) 
8 - Fatal hepatotoxicity 26,278 (65%) 28,384 (44.1) 
Reports combined based on less and severe DILI  
Less severe injury 9484 (23.5%) 18,767 (29.2%) 
Liver failure/hepatotoxicity 30,859 (76.5%) 45,591 (70.8%) 
Reports based on drug label section 
Warning & precautions 26,177 (64.9%) 50,898 (79.1%) 
Box warning 9,939 (24.6%) 12,713 (19.8%) 
Withdrawn 4227 (10.5%) 747 (1.2%) 
Report type 
Direct 1,992 (4.9%) 2,393 (3.7%) 
Expedited 35,569 (88.2%) 57,119 (88.8%) 
Periodic 2,782 (6.9%) 4,846 (7.5%) 
Patient characteristics 
Weight (kg) 
FAERS report counts (n) 7666 (19%) 13532 (21%) 
  Weight missing 32677 (81%) 50826 (79%) 
Weight Mean ± SD 68.6 ± 20.8 70.2 ± 23.4 
Gender 
Male 19,818 (49.1%) 24,353 (37.8%) 
Female 17,711 (43.9%) 34,690 (53.9%) 
Gender missing 2,814 (7%) 5315 (8.3%) 
Age (year) 
FAERS report counts (n) 30,324 (75.2%) 46310 (71.9%) 








Age Mean ± SD 56.1 ± 18.33 48 ± 19.53 
A statistical difference between two DILI groups across categorical variables was performed using 
a chi-square test. Comparisons of continuous variables were performed using t-tests; P values were 
< 0.0001 for all the variables (P<0.05 was considered significant); n is number of instances. 
 
Table 4 Top 20 drugs with the highest reporting odds ratio in both DILI groups.  
Drug class Drug name Severity 
class 
Label section Mitochondrial 
toxicity 
ROR 
Antigout agent Benzbromarone 8 Withdrawn Yes 36.31 
Antidiabetic agent Troglitazone 8 Withdrawn Yes 31.02 
Antimycobacterial Isoniazid 8 Box warning Yes 20.79 
Antimycobacterial Rifampin 8 Warnings and precautions Yes 18.64 
Antibiotics Telithromycin 8 Warnings and precautions No 18.33 
Antineoplastics Gemtuzumab ozogamicin 8 Box warning No 18.08 
Antiarrhythmics Mexiletine 3 Box warning No 17.8 
Antineoplastics Dactinomycin 8 Warnings and precautions No 17.25 
Anti-inflammatory agent Nimesulide 8 Withdrawn Yes 15.07 
Antialcoholics Disulfiram 8 Warnings and precautions No 14.82 
Antivirals Didanosine 8 Warnings and precautions Yes 14.38 
Stimulants; central 
nervous system 
Pemoline 8 Withdrawn No 14.24 
Platelet inhibitors Ticlopidine 4 Warnings and precautions No 13.51 
Antibiotics Trovafloxacin mesylate 8 Withdrawn Yes 13.48 
Antithyroid agents Propylthiouracil 8 Box warning No 13.33 
NSAID Bromfenac 8 Withdrawn No 13.01 
Antiretroviral drugs Stavudine 8 Box warning Yes 12.83 
Hormone modifiers Danazol 8 Box warning Yes 12.82 
Antiparkinson agents Tolcapone 8 Box warning Yes 12.25 
Antivirals Tipranavir 8 Box warning No 12.04 
 
Table 5 Reporting odds ratio estimate for hepatotoxic drugs associated with mitochondrial 
mechanisms of toxicity compared to non-mitochondrial mechanisms. 
DILI group Odds ratio 95% CI P-value 
Drugs associated with 
mitochondrial mechanisms 
of toxicity 
1.43 1.42-1.45 <0.0001 
 
Table 6 Association of age and gender with hepatotoxic drugs with mitochondrial toxicity 
mechanisms as compared with non-mitochondrial mechanisms, using a univariate logistic 







Odds ratio 95% CI P-value 
Age       
<65 years Reference 















Figure 1 Reporting odds ratios (RORs) for hepatotoxic drugs associated with 
mitochondrial mechanisms of toxicity. Benzbromarone, troglitazone, isoniazid, 











Figure 2 Reporting odds ratios (RORs) for hepatotoxic drugs associated with 
non-mitochondrial mechanisms of toxicity. Telithromycin, gemtuzumab ozogamicin, 











Figure 3 Sum of all ROR of “most-DILI-concern” drugs associated with 
mitochondrial and non-mitochondrial mechanisms of toxicity per therapeutic class. 
Drugs from the antineoplastic, antiviral, analgesic, antibiotic, and antimycobacterial 
classes were the top 5 drugs classes associated with higher ROR scores. Drugs from 
the antidiabetic, antiretroviral, anti-inflammatory, anti-Parkinson, vasoactive, 
neuroprotective, and antihyperlipidemic drug classes were primarily associated with 
mitochondrial mechanisms. Alternatively, leukotriene pathway modulators, alcohol 
antagonists, CNS stimulants, and platelet inhibitor drug classes were the drugs with 









Figure 4 Categorization based on liver injury drug label for “most-DILI concern” 
drugs based on their association with mitochondrial and non-mitochondrial 
mechanisms of toxicity. There was not any notable trend between two groups based 
on drug label. 
 
Figure 5 Categorization based on liver injury severity class for “most-DILI concern” 








mechanisms of toxicity. There was not any notable trend between two groups based 
on severity class. 
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